Complex Coronary Valvular and Vascular Cases Conference

Can Coronary Artery Disease Be Eliminated In Our Lifetime?

By Complex Coronary Valvular and Vascular Cases Conference
11/2017
2 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
ASPC 2019 Congress on CVD Prevention

ASPC 2019 Congress on CVD Prevention

Fri, Jul 19, 2019
Cardiometabolic Health Congress (CMHC)

14th Annual Cardiometabolic Health Congress (CMHC)

Thu, Oct 10, 2019
Didactic Presentations

Inova Heart and Vascular Institute 2019 Cardiovascular Symposium

Fri, Apr 26, 2019
See 3 others
Didactic Presentations

Cardiometabolic Health Congress CMHC West 2019

Fri, May 3, 2019
Didactic Presentations

PET Workshop

Sat, May 4, 2019
Didactic Presentations

ESCAPE 2019

Wed, Jun 5, 2019
16:55
William White

Ambulatory Blood Pressure Monitoring

12:37
Stephen Kopecky

Role of PCSK9 Inhibitors in Diabetes

11:08
Craig Beavers

PCSK9 Inhibitors: Pharmacology, Indications, Drug Interactions, Dosing L...

10:48
Northwestern Medicine Cardiovascular Care

Clyde W. Yancy, MD and Neil J. Stone, MD Discuss New Cardiovascular Guid...

Feat. C. Yancy, N. Stone
23:03
Craig Beavers

HIV Heart-Attack: Optimizing Your HIV Patient Post Acute Coronary Syndrome

25:46
ASPC 2018 Congress on CVD Prevention

PCSK9 Inhibitors Today - When, How, and In Whom

Feat. J. Robinson
12:10
Peter Howard Jones

Clinical Trials with PCSK9 Inhibitors and Lipid Efficacy

17:39
Cardiovascular Disease Management - 4th Annual Symposium

Can We Cure Arteriosclerosis? New Thoughts and Concepts and New Game Cha...

10:17
Cleveland Clinic Heart and Vascular Institute

Results of the GLAGOV Trial: Global Assessment of Plaque Regression With...

Feat. S. Nissen
25:21
Cardiometabolic Health Congress (CMHC)

Non-Statin Drugs and New Approaches

Feat. M. Sabatine, C. Ballantyne
19:56
National Lipid Association

Results of REDUCE-IT

Feat. M. Miller
03:03
Cleveland Clinic Heart and Vascular Institute

PCSK9 News from ACC: Recap of FOURIER, EBBINGHAUS substudy, SPIRE & ORION-1

Feat. S. Nissen
14:56
Cardiometabolic Health Congress (CMHC)

Ongoing Initiatives to Overcome Barriers to Access of Newer Cardiovascul...

Feat. D. Mattina
08:13
New Cardiovascular Horizons (NCVH) 2017

Role of Statins and PCSK9 Inhibitors

Feat. C. Walker
16:11
ASPC 2018 Congress on CVD Prevention

Debate – Pro – Lipoprotein(a) – Should Be Measured In All Patients At Hi...

Feat. P. Moriarty
33:18
Cardiology Fiesta 2016

PCSK9 Inhibitors in Clinical Practice

Feat. M. Davidson
21:44
Cardiometabolic Health Congress (CMHC)

Triglycerides and Cardiovascular Disease

Feat. R. Eckel, A. Chait, S. Tsimikas, K. Watson
01:49
Cleveland Clinic Heart and Vascular Institute

Post FOURIER: Who should be treated with PCSK9 inhibitors?

Feat. S. Nissen
19:59
Savitha Subramanian

Utility of PCSK9 Inhibitors in LDL-C Lowering

20:09
Cardiometabolic Health Congress (CMHC)

Best Practices: Effective Management of the Authorization Process for PCSK9

Feat. P. Morris